Your email has been successfully added to our mailing list.

×
0 0 0 0 0.193548387096774 0.730967741935484 0.774193548387097 1.02258064516129
Stock impact report

Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/...

Allakos, Inc (ALLK)  More Company Research Source: GlobeNewswire
Last allakos, inc earnings: 11/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
PDF Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p Treatment response secondary endpoint met with 69% of AK002 treated patients meeting the response criteria vs. 5% on placebo (p = 0.0008)Total symptom score secondary endpoint met with 53% reduction in patient reported total symptom score vs. 24% on placebo (p = 0.0012)In the 14 patients with eosinophilic esophagitis (“EoE”), 13 (93%) patients had esophageal eosinophils reduced to Allakos plans to initiate studies in EG/EGE and EoE in Q1 2020 -- Management to host conference call and webcast today at 8:00 am ET -- REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK) today announced positive results from its Phase 2 randomized, double-blind, placebo-controlled trial of AK002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis. All AK002 dose arms showed clinically meaningful and statistically si [Read more]
Impact snapshot Event time: ALLK
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ALLK alerts
from News Quantified
Opt-in for
ALLK alerts

from News Quantified
Opt-in for
ALLK alerts

from News Quantified